Regulatory effect of inflammatory mediators in spinal cord injury

炎症介质在脊髓损伤中的调节作用

阅读:1

Abstract

Spinal cord injury (SCI) is a severe disabling central nervous system injury that can lead to severe sensory and motor dysfunction, and even paralysis. Depending on the mechanism of injury, SCI can be divided into primary injury and secondary injury. While secondary injury is the most critical stage in the pathophysiological process of SCI, which is the uncontrolled destructive cascade that follows. At present, symptoms are mainly alleviated and endogenous repair mechanisms are improved through drug intervention, surgical decompression and rehabilitation therapy, but they cannot directly promote nerve regeneration and functional recovery. Recently, an increasing number of studies have shown that the inflammatory response is a core link in secondary injury and plays a crucial role in regulating the pathological progression of acute and chronic SCI. Inflammatory mediators are key participants in the inflammatory response, which can trigger various neuropathological conditions and neurological dysfunction and are related to the severity of the injury. They are being explored as potential therapeutic targets for SCI and related diseases. Therefore, reducing the production of pro-inflammatory mediators is feasible and will also become a research hotspot in the future. This article summarizes the main sources of inflammatory mediators related to injury, their expression regulation, the key signaling pathways that regulate their production (such as Toll-like receptors, NF-κB, MAPK pathways, etc.), and their impact on the pathophysiology of SCI. In addition, treatment methods such as chemical antagonists, plant extracts and hormone therapy have been introduced to inhibit the expression of inflammatory mediators in order to control and improve the inflammatory microenvironment. This article mainly relies on preclinical research evidence to deeply analyze the core position of inflammatory mediators, providing a theoretical basis and direction guidance for the development of more effective SCI anti-inflammatory treatments.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。